Compounding Pharmacy Market

The global compounding pharmacy market is projected to reach 19.41 billion by 2030 from USD 14.72 billion in 2025 at a CAGR of 5.7% from 2025 to 2030. The market growth can be credited to persistent drug shortages in North America and Europe and the continued demand-supply gap for GLP-1 drugs.

Several key players in the compounding pharmacy industry with a strong global footprint include Baxter (US), Empower Pharmacy (US), B. Braun (Germany), Fagron (Netherlands), among others. Companies in this sector use various growth strategies to strengthen their international reach and market positions. For example, Baxter and Empower Pharmacy focus on developing customized formulations to meet specific patient needs. Meanwhile, companies like SCA Pharma, Quva, and B. Braun expand their market presence and capabilities through strategic acquisitions.

To know about the assumptions considered for the study download the pdf brochure

Baxter (US) is a leading player in the compounding pharmacy market, offering a broad range of sterile and non-sterile compounding services with a strong presence in developed and emerging markets. The company’s extensive expertise and comprehensive service portfolio have helped it gain a significant market share and establish itself as a dependable partner in biopharmaceutical manufacturing. Baxter also emphasizes inorganic growth strategies, such as acquisitions and strategic partnerships, to expand its capabilities and global presence.

Empower Pharmacy (US) is a leading compounding pharmacy that specializes in customized medications, including sterile and non-sterile formulations, tailored to meet individual patient needs. The company operates one of the largest and most advanced 503A and 503B compounding facilities in the US, ensuring high-quality, compliant, and scalable production. Empower Pharmacy serves healthcare providers, clinics, and hospitals nationwide, focusing on innovation, regulatory excellence, and patient-centered care. The company continues to grow its capabilities and market presence through infrastructure investments and technology-driven compounding solutions.

Market Ranking

The compounding pharmacy market is marked by significant consolidation, with leading players controlling a substantial portion of global revenues, estimated at around 15 to 20% of the total market. These major companies strengthen their positions through strategic acquisitions, advanced manufacturing capabilities, and extensive distribution networks.

Baxter (US) is a leading provider of compounded sterile preparations (CSPs), including oncology injectables, parenteral nutrition, and specialty formulations. The company utilizes its global hospital network and advanced automation technologies. The company continues to enhance its market position through strategic collaborations and investments to expand its compounding capabilities and ready-to-administer product portfolio.

Empower Pharmacy (US) is among the largest 503A and 503B compounding facilities in the country. It provides customized sterile and non-sterile medications to healthcare providers, hospitals, and patients. With a focus on innovation, safety, and compliance, it plays a key role in advancing personalized pharmaceutical care.

B. Braun (Germany) combines compounding expertise with its leadership in infusion therapy and medical devices, providing advanced sterile manufacturing systems and automated parenteral solutions for hospitals worldwide.

Fagron NV (Netherlands) is a global leader in pharmaceutical compounding and personalized medicine, using innovative technologies, software, and automation to support pharmacies and healthcare organizations across major therapeutic areas.

QuVa Pharma (US), an FDA-registered 503B outsourcing facility, focuses on large-scale sterile compounding for hospitals, providing ready-to-administer injectable medications that improve safety and efficiency. Its robust quality systems, nationwide distribution network, and dedication to regulatory excellence establish it as a trusted outsourcing partner in the U.S. compounding pharmacy market.

The compounding pharmacy market rapidly evolves with investments in sterile manufacturing, automation, software-enabled workflow solutions, and personalized medicine. The growing need for patient-specific therapies, regulatory compliance, and advanced hospital pharmacy services drives demand. Favorable reimbursement structures, technological advancements, and strategic partnerships further support growth opportunities for established pharma leaders and emerging compounding firms specialists. The rest of the market, about 80 to 85%, is dominated by regional and independent compounding pharmacies. These companies are gaining ground by focusing on niche areas, forming local partnerships, and adopting new compounding technologies in response to the increasing demand for customized therapies and unique formulations.

Related Reports:

Compounding Pharmacy Market by Product (Oral, Topical, Parenteral), Compounding Type (Ingredient Alteration, Dosage Alteration), Therapeutic Application (Pain Management, HRT), Sterility (Sterile), End User (Pediatric, Adult) - Global forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com